Holding(s) in Company

RNS Number : 8587N

Integumen PLC

23 January 2019

 

Integumen plc

("Integumen" or "the Company")

Changes to interests of a significant shareholder

Integumen plc (AIM: SKIN), the speciality pharmaceutical company, has received a notification of a change in the interests of a significant shareholder. In accordance with AIM Rule 17, the following details are now notified:

a)   Identity of the significant shareholder: Helium Rising Stars Fund

b)   Date of disclosure: 22 January 2019

c)   Date of relevant change: 21 January 2019

d)   Price, amount and class: 21,240,415 ordinary shares of 0.01p each; price not disclosed

e)   Nature of transaction: purchase of shares

f)    Nature and extent of significant shareholder's interest: direct and indirect interests

g)   Resultant shareholding: 38,962,295 shares, with a direct interest in the shares and an indirect interest in the voting rights, in each case amounting to 8.57%

In compliance with DTR5, a copy of the notification received from this investor is appended.

Integumen plc	Gerard Brandon, CEO	[phone]
SPARK Advisory Partners Limited (Nominated Adviser)	Neil Baldwin/Andrew Emmott	[phone]
Hybridan LLP (Broker)	Claire Noyce	[phone]

About Integumen:

Integumen is a vertically integrated business, collaborating their Labskin technology platform with partners in artificial intelligence, clinical research, medical device and life science. These collaborators are building their own technology on top of the Labskin AI backbone. Labskin allows skin-care, health-care, pharmaceutical manufacturers and cosmetic companies to test their products on human-like skin in a real-world environment with full access to multiple state-of-the-art partner technologies.

The Company combines data analytics with access to therapeutic operational expertise and offers solutions to our clients, from regulatory approvals, right through to marketing fully tested ingredients that have been certified on our Laboratory grown living human tissue.

TR-1: Standard form for notification of major holdings

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:			Integumen Plc
1b. Please indicate if the issuer is a non-UK issuer  (please mark with an "X" if appropriate)
2. Reason for the notification (please mark the appropriate box or boxes with an "X")
An acquisition or disposal of voting rights						X
An acquisition or disposal of financial instruments
An event changing the breakdown of voting rights						X
Other (please specify)iii:
3. Details of person subject to the notification obligationiv
Name			Helium Rising Stars Fund
City and country of registered office (if applicable)			Cayman Islands
4. Full name of shareholder(s) (if different from 3.)v
Name
City and country of registered office (if applicable)
5. Date on which the threshold was crossed or reachedvi:			21/01/2019
6. Date on which issuer notified (DD/MM/YYYY):			22/01/2019
7. Total positions of person(s) subject to the notification obligation
	% of voting rights attached to shares (total of 8. A)	% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)		Total of both in % (8.A + 8.B)	Total number of voting rights of issuervii
Resulting situation on the date on which threshold was crossed or reached	8.57%			8.57%	454,826,872
Position of previous notification (if applicable)	4.67%			4.67%

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii
A: Voting rights attached to shares
Class/type of shares ISIN code (if possible)		Number of voting rightsix					% of voting rights
		Direct (Art 9 of Directive 2004/109/EC) (DTR5.1)		Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1)			Direct (Art 9 of Directive 2004/109/EC) (DTR5.1)		Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1)
GB00BYWJ6269		38,962,295					8.57%
SUBTOTAL 8. A		38,962,295					8.57%
B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))
Type of financial instrument		Expiration datex	Exercise/ Conversion Periodxi			Number of voting rights that may be acquired if the instrument is exercised/converted.			% of voting rights
			SUBTOTAL 8. B 1
B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))
Type of financial instrument	Expiration datex		Exercise/ Conversion Period xi		Physical or cash settlementxii			Number of voting rights	% of voting rights
					SUBTOTAL 8.B.2

9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an "X")
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii
Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)
Namexv	% of voting rights if it equals or is higher than the notifiable threshold	% of voting rights through financial instruments if it equals or is higher than the notifiable threshold	Total of both if it equals or is higher than the notifiable threshold
10. In case of proxy voting, please identify:
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held
11. Additional informationxvi

Place of completion	Zürich, Switzerland
Date of completion	22/01/2019

 

 

END

 

 

HOLLIFVDLTIVFIA